Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study AK1113351, a Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) - a Multi-center, Placebo-controlled, Randomized, Double-blind, Parallel-comparison Study

NCT01138007 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01138007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01138007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study AK1113351, a Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD) - a Multi-center, Placebo-controlled, Randomized, Double-blind, Parallel-comparison Study
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
June 17, 2010
Completion date
August 7, 2012
Enrollment
572 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major